Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...
Ladies and gentlemen, thank you for standing by and welcome to the Lilly Q4 2024 earnings call. [Operator instructions] I ...
Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.
Hosted on MSN6h
We Asked Retail Traders About Eli Lilly’s Biggest Post-Q4 Risk — Most Say It’s The Weight-Loss Drug WarsShares of Eli Lilly finished Thursday 3% higher despite an earnings report that showed sales of its blockbuster GLP-1 ...
23hon MSN
Q4 2024 Management View CEO David Ricks highlighted a 45% revenue growth in Q4, with significant contributions from Mounjaro and Zepbound. He emphasized ongoing expansion in manufacturing to meet ...
Pharmaceutical Technology on MSN22h
Novo Nordisk plans new study for CagriSema, targets 2026 submissionCagriSema, considered a successor to Wegovy, is Novo Nordisk’s most likely route of gaining GLP-1RA market share back from ...
24/7 Wall St. on MSN1h
Live Dividend Earnings: SCCO, FTV, KIMThe markets have succumbed to the headline pressure around inflation and tariffs, with all three of the major stock market indices trading in the red as of mid-morning. U.S. job growth slowed in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback